Abstract | PURPOSE: METHODS: A total of 30 patients with macular SC were prospectively randomized into three treatment groups: group D (pulse dexamethasone); group C (pulse cyclophosphamide); and combination (pulse group DCP) administered for 3 days. Macular SC was defined as any active lesion involving/threatening macula. RESULTS: A total of 30 patients were enrolled, with 10 patients in each group. Lesions completely healed at median duration of 2 weeks in each group, with significant improvement in visual acuity compared with pretreatment levels (p<0.05). Pulse cyclophosphamide was most effective in faster healing of lesions compared with other groups. There was no difference in gain in visual acuity between any of the groups (p = 0.32). CONCLUSIONS:
Cyclophosphamide may be an effective treatment modality for acute macular SC, though it may not have a long-term effect on disease relapse.
|
Authors | Pradeep Venkatesh, Akshay Tayade, Varun Gogia, Shikha Gupta, Bhavin M Shah, Rajpal Vohra |
Journal | Ocular immunology and inflammation
(Ocul Immunol Inflamm)
Vol. 26
Issue 3
Pg. 469-476
( 2018)
ISSN: 1744-5078 [Electronic] England |
PMID | 27849419
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Glucocorticoids
- Immunosuppressive Agents
- Dexamethasone
- Cyclophosphamide
|
Topics |
- Adult
- Choroiditis
(drug therapy, physiopathology)
- Cyclophosphamide
(administration & dosage)
- Dexamethasone
(administration & dosage)
- Drug Therapy, Combination
- Female
- Glucocorticoids
(administration & dosage)
- Humans
- Immunosuppression Therapy
- Immunosuppressive Agents
(administration & dosage)
- Injections, Intravenous
- Male
- Prospective Studies
- Pulse Therapy, Drug
- Single-Blind Method
- Treatment Outcome
- Visual Acuity
(physiology)
|